Oral cladribine treatment and idiosyncratic drug-induced liver injury in multiple sclerosis

BACKGROUND: Oral cladribine (OC) is approved for the treatment of highly active relapsing multiple sclerosis. Postmarketing safety assessments have reported rare, but occasionally severe cases of liver injury in temporal association with OC, with pathophysiologic mechanisms still unknown. In the onl...

Descripción completa

Detalles Bibliográficos
Autores principales: Rakers, Florian, Fritsch, Almut, Herrmann, Andreas, Tannapfel, Andrea, Schwab, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496679/
https://www.ncbi.nlm.nih.gov/pubmed/37705760
http://dx.doi.org/10.1136/bmjno-2023-000481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496679/
https://www.ncbi.nlm.nih.gov/pubmed/37705760
http://dx.doi.org/10.1136/bmjno-2023-000481

Ejemplares similares